Small cell lung cancer research hub

Debio 0123 in combination with carboplatin and etoposide in adult participants with small cell lung cancer that recurred or progressed after platinum-based therapy.

This study is looking at a new treatment called Debio 0123 combined with standard chemotherapy for adults with a type of lung cancer called small cell lung cancer. Participants will have already had treatment that didn't stop their cancer from growing or coming back, and are looking for other options.

A Study to Learn About How Different Formulations of the Medicine Called Mevrometostat are Taken up Into the Blood in Healthy Adult Participants

This study looks at how a new medicine, Mevrometostat, is absorbed by the body. It's for healthy adults and is an early step in researching potential treatments for certain cancers like lung, prostate, and lymphoma.

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

This study looks at new drug combinations for a type of lung cancer called Limited-Stage Small Cell Lung Cancer (LS-SCLC). Researchers want to see if adding pembrolizumab and olaparib to standard treatments helps people live longer.

A Study of MGC026 in Participants With Advanced Solid Tumors

This study is testing a new medicine called MGC026 for people with advanced cancers that have come back or spread. Doctors want to see if it's safe, what side effects it causes, and if it can help slow down or shrink tumors.

TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO

This study, called TRACERx EVO, looks at how lung cancer and mesothelioma change during treatment. It involves collecting information and samples from patients with early or advanced disease to help doctors understand the illnesses better and find new ways to treat them.

A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice

This study looks at how a cancer drug called atezolizumab works in real patients. Researchers want to see its effects and safety under normal hospital care, for different types of cancer it's approved for.

A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer

This study looks at treating a specific type of advanced lung cancer. It compares two treatments, atezolizumab alone or combined with lurbinectedin, after initial chemotherapy. The aim is to see which approach works best to keep the cancer stable.

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

This study is looking at a new medicine called ifinatamab deruxtecan (I-DXd) for small cell lung cancer that has come back. It compares I-DXd to standard treatments to see if it works better and is safe.

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

This study is looking at a new treatment called BNT327 for tiny-cell lung cancer. It combines BNT327 with chemotherapy to see how safe and effective it is for people whose cancer is widespread or has come back after other treatments.

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

This study is testing a new drug, rezatapopt, for advanced cancers with a specific gene change (TP53 Y220C). It's also looking at rezatapopt with another drug, pembrolizumab, to see how safe and effective they are. It’s for people who have already had cancer treatment.

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

This study looks at new treatments (Durvalumab, Tremelimumab) for a type of lung cancer, Small Cell Lung Cancer, after initial strong treatment. It aims to see if these drugs can stop the cancer from coming back.

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

This study is testing new medicines, Gocatamig and Ifinatamab Deruxtecan (I-DXd), for advanced small cell lung cancer that has come back or isn't responding to treatment. Researchers want to see if these drugs, alone or together, are safe and can shrink the cancer.

SPECT/CT imaging of FPI-2505 in patients with solid tumours; a phase 0 molecular imaging basket trial (SCOPE-study).

This early-stage study is looking at a new way to take pictures inside the body to help understand how certain cancers behave. It focuses on several types of solid tumours, including lung, bowel, breast, and pancreatic cancer, and involves adults of all genders.

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

This study looks at a new drug, Tarlatamab, for people with a type of lung cancer called limited-stage small-cell lung cancer (LS-SCLC). It aims to see if Tarlatamab can help people live longer without their cancer getting worse after chemotherapy and radiotherapy.

DAREON®-Lung-1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer.

This study looks at a new drug, obrixtamig, alongside usual treatment for extensive small cell lung cancer. It aims to see if this new combination helps people live longer and feel better compared to the usual treatment alone.

68Ga satoreotide trizoxetan PET/CT in patients with high grade neuroendocrine lung cancer